299 related articles for article (PubMed ID: 7903204)
1. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
2. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
Tahara H; Zitvogel L; Storkus WJ; Zeh HJ; McKinney TG; Schreiber RD; Gubler U; Robbins PD; Lotze MT
J Immunol; 1995 Jun; 154(12):6466-74. PubMed ID: 7759882
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cell.
Iwazawa T; Chau GY; Mori T; Dookeran KA; Rubin JT; Watkins S; Robbins PD; Lotze MT; Tahara H
Cancer Gene Ther; 2001 Jan; 8(1):17-22. PubMed ID: 11219489
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
7. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
9. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
Pappo I; Tahara H; Robbins PD; Gately MK; Wolf SF; Barnea A; Lotze MT
J Surg Res; 1995 Feb; 58(2):218-26. PubMed ID: 7861776
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-12 gene transfection into murine B16 melanoma cells suppresses tumorigenicity and decreases metastatic potential].
Fu J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Aug; 78(8):627-9. PubMed ID: 11038817
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
13. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
15. Cloning and expression of murine IL-12.
Schoenhaut DS; Chua AO; Wolitzky AG; Quinn PM; Dwyer CM; McComas W; Familletti PC; Gately MK; Gubler U
J Immunol; 1992 Jun; 148(11):3433-40. PubMed ID: 1350290
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
19. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of murine Lewis lung cancer with recombinant interleukin-12].
Yin XL; Duan H; Peng ZP; Sun SL; Li SL
Ai Zheng; 2006 Sep; 25(9):1087-91. PubMed ID: 16965647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
